Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPIX NASDAQ:GUTS OTCMKTS:PRVCF NYSE:RFL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPIXCumberland Pharmaceuticals$3.44+0.3%$3.36$1.04▼$7.25$51.31M-0.3734,065 shs23,314 shsGUTSFractyl Health$1.02$1.32$0.83▼$3.48$51.30M1.55635,025 shs1.68 million shsPRVCFPreveCeutical Medical$0.02+2.4%$0.02$0.01▼$0.03$12.10M0.49138,759 shs201,200 shsRFLRafael$1.35+1.5%$1.73$1.28▼$3.19$46.67M0.89105,982 shs161,091 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPIXCumberland Pharmaceuticals+1.18%-6.28%+17.87%-34.54%+157.89%GUTSFractyl Health+3.03%+13.36%+3.67%-50.49%-65.54%PRVCFPreveCeutical Medical-2.75%+0.95%-15.20%-20.90%+70.97%RFLRafael-0.30%-8.09%-18.68%-34.90%-12.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPIXCumberland Pharmaceuticals$3.44+0.3%$3.36$1.04▼$7.25$51.31M-0.3734,065 shs23,314 shsGUTSFractyl Health$1.02$1.32$0.83▼$3.48$51.30M1.55635,025 shs1.68 million shsPRVCFPreveCeutical Medical$0.02+2.4%$0.02$0.01▼$0.03$12.10M0.49138,759 shs201,200 shsRFLRafael$1.35+1.5%$1.73$1.28▼$3.19$46.67M0.89105,982 shs161,091 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPIXCumberland Pharmaceuticals+1.18%-6.28%+17.87%-34.54%+157.89%GUTSFractyl Health+3.03%+13.36%+3.67%-50.49%-65.54%PRVCFPreveCeutical Medical-2.75%+0.95%-15.20%-20.90%+70.97%RFLRafael-0.30%-8.09%-18.68%-34.90%-12.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPIXCumberland Pharmaceuticals 0.00N/AN/AN/AGUTSFractyl Health 3.00Buy$6.53540.52% UpsidePRVCFPreveCeutical Medical 0.00N/AN/AN/ARFLRafael 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRVCF, CPIX, RFL, and GUTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025GUTSFractyl HealthLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.608/14/2025GUTSFractyl HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $6.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPIXCumberland Pharmaceuticals$37.87M1.36$0.26 per share13.34$1.61 per share2.14GUTSFractyl Health$17K3,017.34N/AN/A$0.59 per share1.73PRVCFPreveCeutical MedicalN/AN/AN/AN/A($0.01) per shareN/ARFLRafael$640K74.02N/AN/A$3.51 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPIXCumberland Pharmaceuticals-$6.48M-$0.22N/A∞N/A-6.97%7.48%2.66%11/6/2025 (Estimated)GUTSFractyl Health-$68.69M-$2.06N/AN/AN/A-73,864.52%-584.35%-102.88%11/11/2025 (Estimated)PRVCFPreveCeutical Medical-$860KN/A0.00∞N/AN/AN/A-821.91%N/ARFLRafael-$34.41M-$0.94N/A∞N/A-3,127.60%-24.75%-21.12%11/5/2025 (Estimated)Latest PRVCF, CPIX, RFL, and GUTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GUTSFractyl Health-$0.37-$0.53-$0.16-$0.57N/AN/A8/5/2025Q2 2025CPIXCumberland PharmaceuticalsN/A$0.02N/A-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/APRVCFPreveCeutical MedicalN/AN/AN/AN/AN/ARFLRafaelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPIXCumberland Pharmaceuticals0.191.301.17GUTSFractyl Health4.611.221.22PRVCFPreveCeutical MedicalN/A0.010.01RFLRafaelN/A3.853.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPIXCumberland Pharmaceuticals15.51%GUTSFractyl HealthN/APRVCFPreveCeutical MedicalN/ARFLRafael11.30%Insider OwnershipCompanyInsider OwnershipCPIXCumberland Pharmaceuticals44.85%GUTSFractyl Health26.10%PRVCFPreveCeutical MedicalN/ARFLRafael10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableGUTSFractyl Health10250.29 million37.16 millionN/APRVCFPreveCeutical MedicalN/A570.65 millionN/ANot OptionableRFLRafael2035.09 million31.51 millionOptionablePRVCF, CPIX, RFL, and GUTS HeadlinesRecent News About These CompaniesRafael (NYSE:RFL) Lowered to "Sell" Rating by Wall Street ZenSeptember 8, 2025 | marketbeat.comIeq Capital LLC Takes Position in Rafael Holdings, Inc. $RFLSeptember 7, 2025 | marketbeat.comRafael (NYSE:RFL) Cut to "Sell" at Wall Street ZenSeptember 6, 2025 | americanbankingnews.comRafael Holdings, Inc. (NYSE:RFL) Sees Large Decline in Short InterestSeptember 4, 2025 | marketbeat.comRafael (NYSE:RFL) Shares Down 3.6% - Here's WhySeptember 3, 2025 | marketbeat.comRafael Holdings, Inc. Subsidiary Cyclo Therapeutics to Present New Data on Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 at ICIEM 2025August 27, 2025 | quiverquant.comQRafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)August 27, 2025 | globenewswire.comNew Photo of Rafael Nadal and Roger Federer Emerges on TuesdayJuly 26, 2025 | msn.comRafael Leao pays heartfelt tribute to Diogo Jota as Milan beat LiverpoolJuly 26, 2025 | msn.comRafael Leao, Kenny Dalglish and Hong Kong crowd honor Diogo Jota in Liverpool preseason friendlyJuly 26, 2025 | msn.comRafael Leao's touching tribute to Diogo Jota vs Liverpool as club make statementJuly 26, 2025 | mirror.co.ukMRafael Devers makes his debut at first base for Giants after refusing to play position for Red SoxJuly 25, 2025 | sfexaminer.comSRafael Devers Player Props: July 25, Giants vs. MetsJuly 25, 2025 | sportsbookwire.usatoday.comWatch: Roger Federer visits Rafael Nadal's AcademyJuly 18, 2025 | msn.comKaiser Lays Off Dozens Of Nurses In Petaluma, San Rafael: ReportJuly 18, 2025 | msn.comGolf: Packed field for 4th annual San Rafael City ChampionshipJuly 18, 2025 | marinij.comMGiants Boss Says It's 'Just a Matter of Time' Until Rafael Devers Catches FireJuly 18, 2025 | msn.comRafael Leao hits back after more bitter Cassano criticismJuly 18, 2025 | sports.yahoo.comMilan’s new formula? Massimiliano Allegri to use Cristiano Ronaldo blueprint to unleash Rafael Leao—With Christian Pulisic as the key cogJuly 18, 2025 | worldsoccertalk.comWRoger Federer reunites with Rafael Nadal - From Centre Court to MallorcaJuly 18, 2025 | msn.comSan Rafael Is Seeking Artists For 5 Downtown ProjectsJuly 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRVCF, CPIX, RFL, and GUTS Company DescriptionsCumberland Pharmaceuticals NASDAQ:CPIX$3.44 +0.01 (+0.29%) Closing price 04:00 PM EasternExtended Trading$3.44 0.00 (-0.15%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Fractyl Health NASDAQ:GUTS$1.02 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.03 +0.01 (+0.98%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.PreveCeutical Medical OTCMKTS:PRVCF$0.02 +0.00 (+2.36%) As of 01:59 PM EasternPreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada.Rafael NYSE:RFL$1.35 +0.02 (+1.50%) Closing price 03:58 PM EasternExtended Trading$1.38 +0.03 (+2.15%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
